Jay K Kolls Selected Research

Pneumocystis Infections

1/2021	Effect of Subcutaneous Anti-CD20 Antibody-Mediated B Cell Depletion on Susceptibility to Pneumocystis Infection in Mice.
1/2019	CD4+ T Cell Regulation of Antibodies Cross-Reactive with Fungal Cell Wall-Associated Carbohydrates after Pneumocystis murina Infection.
10/2016	A Novel CD4+ T Cell-Dependent Murine Model of Pneumocystis-driven Asthma-like Pathology.
5/2015	Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.
6/2014	Novel pneumocystis antigen discovery using fungal surface proteomics.
12/2005	CD4+ T cell-independent DNA vaccination against opportunistic infections.
2/2005	Immunity against the opportunistic fungal pathogen Pneumocystis.
11/2002	Local delivery of the viral interleukin-10 gene suppresses tissue inflammation in murine Pneumocystis carinii infection.
9/2002	Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jay K Kolls Research Topics

Disease

77	Infections 01/2022 - 01/2002
55	Inflammation (Inflammations) 07/2022 - 11/2002
22	Asthma (Bronchial Asthma) 01/2021 - 09/2008
19	Pneumonia (Pneumonitis) 01/2021 - 11/2002
17	Neoplasms (Cancer) 01/2021 - 09/2003
14	Cystic Fibrosis (Mucoviscidosis) 07/2022 - 01/2005
11	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 10/2004
11	Human Influenza (Influenza) 01/2019 - 10/2009
9	Pneumocystis Infections 01/2021 - 09/2002
7	COVID-19 01/2022 - 01/2021
7	Arthritis (Polyarthritis) 12/2011 - 03/2003
6	Coinfection 01/2021 - 01/2006
6	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 01/2021 - 09/2002
6	Candidiasis (Moniliasis) 01/2020 - 01/2012
5	Lung Diseases (Lung Disease) 01/2019 - 02/2007
5	Respiratory Syncytial Virus Infections 01/2017 - 09/2005
4	Virus Diseases (Viral Diseases) 01/2021 - 10/2009
4	Bacterial Pneumonia 01/2021 - 03/2008
4	Opportunistic Infections (Opportunistic Infection) 01/2020 - 12/2005
4	Melanoma (Melanoma, Malignant) 06/2017 - 09/2003
4	Lung Injury 01/2017 - 02/2006
4	Bacterial Infections (Bacterial Infection) 01/2017 - 01/2006
3	Critical Illness (Critically Ill) 01/2020 - 01/2006
3	Hepatitis 11/2019 - 12/2008
3	Fibrosis (Cirrhosis) 11/2019 - 09/2008
3	Pneumococcal Infections 11/2019 - 05/2015
3	Mycoses (Diseases, Fungus) 01/2019 - 09/2013
3	Tuberculosis (Tuberculoses) 10/2017 - 11/2011
3	Immune Reconstitution Inflammatory Syndrome 01/2017 - 11/2002
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/2016 - 03/2009
3	Communicable Diseases (Infectious Diseases) 06/2014 - 07/2013
3	Respiratory Hypersensitivity 01/2014 - 09/2008
3	Weight Loss (Weight Reduction) 01/2013 - 05/2006
3	Cryptococcosis 12/2012 - 12/2010
3	Rheumatoid Arthritis 04/2010 - 09/2005
3	Experimental Arthritis 04/2010 - 03/2003
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 06/2009 - 04/2007
2	Colitis 01/2021 - 05/2006
2	Multiple Sclerosis 01/2021 - 07/2011
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2017
2	Body Weight (Weight, Body) 01/2021 - 10/2010
2	Emphysema 01/2020 - 01/2011
2	Dysbiosis 11/2019 - 03/2016
2	Disease Progression 11/2019 - 01/2014
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 11/2019 - 03/2011
2	Pneumococcal Pneumonia 11/2019 - 01/2016
2	Granuloma 01/2019 - 10/2017

Drug/Important Bio-Agent (IBA)

76	Interleukin-17 (Interleukin 17)IBA 01/2021 - 01/2003
43	CytokinesIBA 07/2022 - 11/2002
21	Interleukin-22 (IL-22)IBA 01/2021 - 03/2008
15	Interleukin-17 ReceptorsIBA 01/2018 - 01/2005
13	AntigensIBA 01/2021 - 12/2005
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2006
12	Interleukin-23 (Interleukin 23)IBA 01/2017 - 05/2003
11	VaccinesIBA 12/2016 - 12/2005
9	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 11/2002
9	InterleukinsIBA 01/2021 - 04/2010
8	Interferon-gamma (Interferon, gamma)IBA 01/2021 - 09/2002
8	ChemokinesIBA 01/2021 - 02/2007
7	Pharmaceutical PreparationsIBA 01/2021 - 01/2012
7	LigandsIBA 11/2019 - 03/2003
7	Interleukin-6 (Interleukin 6)IBA 11/2019 - 05/2006
7	Interleukin-13IBA 05/2015 - 05/2009
7	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014 - 01/2002
6	RNA (Ribonucleic Acid)IBA 01/2021 - 07/2015
6	Ethanol (Ethyl Alcohol)IBA 05/2015 - 03/2003
5	Immunoglobulin G (IgG)IBA 11/2019 - 05/2006
5	AllergensIBA 10/2016 - 10/2009
5	OvalbuminIBA 09/2014 - 01/2010
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 05/2014 - 05/2002
4	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 12/2005
4	Estrogens (Estrogen)FDA Link 01/2021 - 09/2005
4	interleukin-22 receptor (IL-22R)IBA 11/2019 - 10/2010
4	Messenger RNA (mRNA)IBA 01/2019 - 01/2002
4	SteroidsIBA 01/2015 - 09/2008
3	Cystic Fibrosis Transmembrane Conductance Regulator (Protein, CFTR)IBA 12/2021 - 02/2006
3	InterferonsIBA 01/2021 - 01/2014
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2021 - 01/2015
3	Cholecalciferol (Vitamin D3)FDA Link 01/2020 - 09/2010
3	AntibodiesIBA 01/2019 - 12/2010
3	Transcription Factors (Transcription Factor)IBA 10/2017 - 04/2006
3	Antiviral Agents (Antivirals)IBA 01/2017 - 08/2014
3	Biomarkers (Surrogate Marker)IBA 07/2015 - 04/2012
3	Interleukin-10 (Interleukin 10)IBA 02/2015 - 11/2002
3	Toll-Like Receptor 4IBA 05/2014 - 05/2003
3	Chemotactic FactorsIBA 01/2014 - 08/2006
3	Interleukin-23 Subunit p19IBA 12/2009 - 07/2005
3	Interleukin-1 (Interleukin 1)IBA 05/2006 - 03/2005
2	Estrogen ReceptorsIBA 01/2021 - 01/2017
2	IntegrinsIBA 01/2021 - 12/2002
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2019
2	Peptides (Polypeptides)IBA 01/2021 - 03/2013
2	SmokeIBA 01/2020 - 01/2011
2	Vitamin D FDA LinkGeneric 01/2020 - 01/2015
2	carbapenemaseIBA 01/2020 - 12/2016
2	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2019 - 09/2005
2	polyglucosanIBA 01/2019 - 01/2019

Therapy/Procedure

23	Therapeutics 12/2021 - 01/2005
5	Immunotherapy 01/2020 - 02/2007
4	Highly Active Antiretroviral Therapy (HAART) 01/2006 - 11/2002